Adbiotech KRX:179530KOSDAQ
애드바이오텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Adbiotech reported revenue of ₩2.9bn, up 2.0% year on year, and an operating loss of ₩1.9bn. Adbiotech (애드바이오텍) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals New 5% holder Major holder adding Screener
Adbiotech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.9bn | +2.0% | −₩1.9bn margin −66.6% | −₩284m |
| Q1 2026 | ₩3.1bn | -11.1% | −₩1.1bn margin −34.6% | −₩5.4bn |
| Q4 2025 derived | ₩3.0bn | -36.0% | ₩346m margin 11.6% | ₩6.9bn |
| Q3 2025 | ₩3.6bn | +109.3% | −₩1.8bn margin −48.5% | −₩4.8bn |
| Q2 2025 | ₩2.8bn | +15.1% | −₩1.9bn margin −66.3% | −₩4.9bn |
| Q1 2025 | ₩3.5bn | +17.9% | −₩200m margin −5.8% | −₩601m |
| Q4 2024 derived | ₩4.6bn | +101.6% | −₩723m margin −15.6% | −₩932m |
| Q3 2024 | ₩1.7bn | -37.2% | −₩1.1bn margin −64.6% | −₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Adbiotech top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Adbiotech news Korean headlines
No articles yet.